Kiji Therapeutics develops state-of-the-art off-the-shelf engineered cell therapies for multiple life-threatening diseases. Incorporated in France and Spain in 2023 with an initial seed from AdBio Partners. Kiji Tx has international Scientific Founders, Management and Scientific/Clinical Advisory Board, experienced in C&GT and product clinical development. With access to R&D and GMP manufacturing facilities in Madrid and Navara, Spain, Kiji Tx has operational readiness to develop the cell engineered platform and move to the clinic with its lead product, with a first patient expected in 2024. The company’s vision is to gene engineer iPSC-derived MSC cells for a targeted and optimized therapeutic benefit in a broad set of disease areas.